Exhibit 99.1 Supernus Announces First Quarter 2024 Financial Results ROCKVILLE, MD, May 8, 2024 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter of 2024 and associated Company developments. "We are pleased to announce another strong quarter for Qelbree, which delivered robust growth of 75% in net sales compared to t ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Peter Vozzo - IR Jack Khattar - CEO Tim Dec - CFO Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Stacy Ku - TD Cowen Jack Padovano - Stifel Operator Good afternoon, and welcome to the Supernus Pharmaceuticals' Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2023 or ☐ TRANSMISSION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | 20-2590184 | | - ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Peter Vozzo – Investor Relations Jack Khattar – Chief Executive Officer Tim Dec – Chief Financial Officer Conference Call Participants Andrew Tsai – Jefferies Operator Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer sessio ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2023 was $135.5 million, down from $170.1 million in the same quarter last year, with net product sales of $128.3 million and royalty revenue of $7.2 million [41][42] - The decrease in net product sales was primarily due to a $52.3 million decline in Trokendi XR, partially offset by a $24 million increase in net sales from growth products Qelbree and GOCOVRI [42][43] - GAAP net loss for Q2 2023 was $800,000, or loss per diluted share of $0.02, compared to GAAP net earnings of $7.9 million, or earnings per diluted share of $0.14 in the same period last year [45] - For the first half of 2023, total revenue was $289.3 million, down from $322.6 million in the same period last year, with a similar trend in net product sales [46][47] Business Line Data and Key Metrics Changes - Qelbree and GOCOVRI achieved combined net sales of $60 million in Q2 2023, representing a 67% growth compared to the same period last year [13] - Qelbree's prescriptions grew by 9% in Q2 2023, reaching an all-time high of 146,344 quarterly prescriptions, which is a 133% increase compared to Q2 2022 [15][16] - GOCOVRI's net product sales increased to $29 million in Q2 2023, a 17% increase over the same period in 2022 [34] - Oxtellar XR net product sales were $24 million, down from $30 million in the same period last year, primarily due to destocking by wholesalers [35] Market Data and Key Metrics Changes - The ADHD market was essentially flat in Q2 2023 compared to Q1 2023, while Qelbree's prescriptions showed significant growth [15] - The adult segment for Qelbree grew by approximately 16%, while the pediatric segment grew by 5%-6% [23] - Pharmacy orders from wholesalers have significantly increased in early August, indicating a positive trend ahead of the back-to-school season [17] Company Strategy and Development Direction - The company is focused on making the 2023 transition smooth while moving away from legacy products and setting the stage for growth in 2024 and beyond [3] - The company plans to host an R&D Day on October 18, 2023, to provide insights into its product pipeline, emphasizing SPN-817 and SPN-820 [37][38] - The company continues to prioritize commercial assets for business development while remaining open to pipeline assets that could be launched in the near future [75][76] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Qelbree, citing its unique clinical profile and increasing adoption among physicians [33][85] - The company expects sales to continue to grow in Q3 and Q4, driven by the back-to-school season [63] - Management noted that the stimulant shortages may not significantly benefit Qelbree, as physicians may opt for alternative stimulants rather than switching to non-stimulants [91] Other Important Information - The company had approximately $189.1 million in cash and marketable securities as of June 30, 2023, down from $555.2 million at the end of 2022, primarily due to the repayment of convertible senior notes [51][52] - The company reiterated its financial guidance for total revenue in 2023, expecting it to range from $580 million to $620 million [53] Q&A Session Summary Question: Can you comment on Qelbree's net price and any inventory fluctuations in Q2? - Management indicated that orders from pharmacies are showing a healthy increase, which is a positive leading indicator for future sales [58] Question: How does the sales trajectory for Qelbree look for Q3 and Q4? - Management expects prescriptions to pick up in Q3 and continue growing into Q4 due to the back-to-school season [63] Question: What are the underlying volume trends for GOCOVRI? - Management estimated prescription growth for GOCOVRI to be around 6% in the first half of the year, indicating healthy growth [73] Question: What is the company's strategy regarding business development? - The company continues to prioritize commercial assets while also considering pipeline assets that could be launched in the near future [75] Question: Can you explain the rationale behind the recent settlement regarding Oxtellar XR? - Management decided to settle to mitigate risks and allocate resources more effectively towards key brands like Qelbree and GOCOVRI [78]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | | 20- ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Jack Padovano - Stifel Operator Good afternoon, and welcome to Supernus Pharmaceuticals First Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | | | 20 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2022 or ☐ TRANSMISSION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-35518 (Address of Principal Executive Offices) (zip code) (301) 838-2500 (Registrant's telephone number, including area cod ...